Lumican and tumor therapy resistance

doi:10.3760/cma.j.cn371439-20220621-00018

Abstract

Abstract:

Lumican is a member of the small leucine-rich proteoglycan family，which is involved in cell processes related to tumorigenesis and development，such as epithelial-mesenchymal transition，cell proliferation，migration，invasion and adhesion. The expression of Lumican in different tumors is positively or negatively correlated with tumor progression，and can be used as a reference for tumor prognosis and efficacy evaluation. Further study of the correlation and potential mechanism between Lumican and tumor therapy resistance can provide new ideas for predicting clinical therapeutic efficacy.

Key words: Neoplasms, Lumican, Therapy resistance

Hu Ge, Xia Fan, Wu Xueya, Wang Yun, Xu Xiuli. Lumican and tumor therapy resistance[J]. Journal of International Oncology, 2023, 50(2): 87-90.

References 33

[1]	Matsushima N, Miyashita H, Kretsinger RH. Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans[J]. J Cell Commun Signal, 2021, 15(4): 519-531. DOI: 10.1007/s12079-021-00616-4. doi: 10.1007/s12079-021-00616-4
[2]	Zappia J, Joiret M, Sanchez C, et al. From translation to protein degradation as mechanisms for regulating biological functions: a review on the SLRP family in skeletal tissues[J]. Biomolecules, 2020, 10(1): 80. DOI: 10.3390/biom10010080. doi: 10.3390/biom10010080
[3]	Matsushima N, Miyashita H, Tamaki S, et al. Shrinking of repeating unit length in leucine-rich repeats from double-stranded DNA viruses[J]. Arch Virol, 2021, 166(1): 43-64. DOI: 10.1007/s00705-020-04820-2. doi: 10.1007/s00705-020-04820-2 pmid: 33052487
[4]	Halari CD, Zheng M, Lala PK. Roles of two small leucine-rich proteoglycans decorin and biglycan in pregnancy and pregnancy-associated diseases[J]. Int J Mol Sci, 2021, 22(19): 10584. DOI: 10.3390/ijms221910584. doi: 10.3390/ijms221910584
[5]	Nizet P, Untereiner V, Sockalingum GD, et al. Assessment of ovarian tumor growth in wild-type and lumican-deficient mice: insights using infrared spectral imaging, histopathology, and immunohistochemistry[J]. Cancers (Basel), 2021, 13(23): 5950. DOI: 10.3390/cancers13235950. doi: 10.3390/cancers13235950
[6]	Liu C, Hu Y, Wang Z, et al. The downregulation of placental lumican promotes the progression of preeclampsia[J]. Reprod Sci, 2021, 28(11): 3147-3154. DOI: 10.1007/s43032-021-00660-w. doi: 10.1007/s43032-021-00660-w pmid: 34231169
[7]	Lee YS, Park SJ, Lee JY, et al. Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates[J]. Korean J Intern Med, 2022, 37(4): 821-829. DOI: 10.3904/kjim.2022.015. doi: 10.3904/kjim.2022.015
[8]	Lee JY, Park SJ, Kim DA, et al. Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal[J]. Front Cell Dev Biol, 2020, 8:565826. DOI: 10.3389/fcell.2020.565826. doi: 10.3389/fcell.2020.565826
[9]	de Wit M, Carvalho B, Delis-van Diemen PM, et al. Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression[J]. PLoS One, 2017, 12(5): e0174768. DOI: 10.1371/journal.pone.0174768. doi: 10.1371/journal.pone.0174768
[10]	Appunni S, Anand V, Khandelwal M, et al. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): plausible diagnostic marker in urothelial carcinoma of bladder[J]. Tumour Biol, 2017, 39(5): 1010428317699112. DOI: 10.1177/1010428317699112. doi: 10.1177/1010428317699112
[11]	Appunni S, Rubens M, Ramamoorthy V, et al. Lumican, pro-tumorigenic or anti-tumorigenic: a conundrum[J]. Clin Chim Acta, 2021, 514: 1-7. DOI: 10.1016/j.cca.2020.12.011. doi: 10.1016/j.cca.2020.12.011 pmid: 33333043
[12]	Yamauchi N, Kanke Y, Saito K, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma[J]. Oncol Lett, 2021, 21(6): 445. DOI: 10.3892/ol.2021.12706. doi: 10.3892/ol.2021.12706 pmid: 33868483
[13]	Zang Y, Dong Q, Lu Y, et al. Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma[J]. Aging (Albany NY), 2021, 13(3): 4388-4408. DOI: 10.18632/aging.202401. doi: 10.18632/aging.202401
[14]	Lee JY, Kim DA, Kim EY, et al. Lumican inhibits osteoclastoge-nesis and bone resorption by suppressing Akt activity[J]. Int J Mol Sci, 2021, 22(9): 4717. DOI: 10.3390/ijms22094717. doi: 10.3390/ijms22094717
[15]	Klejewski A, Sterzyńska K, Wojtowicz K, et al. The significance of lumican expression in ovarian cancer drug-resistant cell lines[J]. Oncotarget, 2017, 8(43): 74466-74478. DOI: 10.18632/oncotarget.20169. doi: 10.18632/oncotarget.20169 pmid: 29088800
[16]	Li X, Truty MA, Kang Y, et al. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery[J]. Clin Cancer Res, 2014, 20(24): 6529-6540. DOI: 10.1158/1078-0432.CCR-14-0970. doi: 10.1158/1078-0432.CCR-14-0970 pmid: 25336691
[17]	Li X, Roife D, Kang Y, et al. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition[J]. Oncogene, 2016, 35(37): 4881-4890. DOI: 10.1038/onc.2016.20. doi: 10.1038/onc.2016.20 pmid: 26876211
[18]	Li X, Kang Y, Roife D, et al. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth[J]. Oncogene, 2017, 36(38): 5432-5438. DOI: 10.1038/onc.2017.125. doi: 10.1038/onc.2017.125 pmid: 28534517
[19]	Sarcar B, Li X, Fleming JB. Hypoxia-induced autophagy degrades stromal lumican into tumor microenvironment of pancreatic ductal adenocarcinoma: a mini-review[J]. J Cancer Treatment Diagn, 2019, 3(1): 22-27. DOI: 10.29245/2578-2967/2019/1.1165. doi: 10.29245/2578-2967/2019/1.1165 pmid: 31406961
[20]	Kihira K, Chelakkot VS, Kainuma H, et al. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells[J]. Int J Hematol, 2020, 112(6): 795-806. DOI: 10.1007/s12185-020-02981-z. doi: 10.1007/s12185-020-02981-z
[21]	Yu Z, Liu L, Shu Q, et al. Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells[J]. Oncol Lett, 2019, 18(4): 4317-4327. DOI: 10.3892/ol.2019.10767. doi: 10.3892/ol.2019.10767 pmid: 31579426
[22]	Li D, Lin TL, Lipe B, et al. A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics[J]. Leuk Res, 2018, 72: 105-112. DOI: 10.1016/j.leukres.2018.08.012. doi: 10.1016/j.leukres.2018.08.012
[23]	张永丽, 张若佳, 范焕彩, 等. TXNDC5-Prx2途径对前列腺癌细胞耐药性的调控[J]. 国际肿瘤学杂志, 2021, 48(8): 473-478. DOI: 10.3760/cma.j.cn371439-20210324-00090. doi: 10.3760/cma.j.cn371439-20210324-00090
[24]	Wang JL, Wang Y, Ren GP. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods[J]. J Zhejiang Univ Sci B, 2020, 21(3): 246-255. DOI: 10.1631/jzus.B1900329. doi: 10.1631/jzus.B1900329
[25]	Athanasiou A, Tennstedt P, Wittig A, et al. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology[J]. PLoS One, 2021, 16(11): e0259093. DOI: 10.1371/journal.pone.0259093. doi: 10.1371/journal.pone.0259093
[26]	Li Y, Su Z, Zhao W, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity[J]. Nat Cancer, 2020, 1(9): 882-893. DOI: 10.1038/s43018-020-0095-6. doi: 10.1038/s43018-020-0095-6
[27]	Momin N, Mehta NK, Bennett NR, et al. Anchoring of intratumo-rally administered cytokines to collagen safely potentiates systemic cancer immunotherapy[J]. Sci Transl Med, 2019, 11(498): eaaw2614. DOI: 10.1126/scitranslmed.aaw2614. doi: 10.1126/scitranslmed.aaw2614
[28]	Jeanne A, Untereiner V, Perreau C, et al. Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide[J]. Sci Rep, 2017, 7(1): 7700. DOI: 10.1038/s41598-017-07043-9. doi: 10.1038/s41598-017-07043-9 pmid: 28794454
[29]	Brézillon S, Untereiner V, Mohamed HT, et al. Label-free infrared spectral histology of skin tissue part Ⅱ: impact of a lumican-derived peptide on melanoma growth[J]. Front Cell Dev Biol, 2020, 8: 377. DOI: 10.3389/fcell.2020.00377. doi: 10.3389/fcell.2020.00377 pmid: 32548117
[30]	Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma[J]. Int J Cancer, 2010, 126(2): 437-449. DOI: 10.1002/ijc.24704. doi: 10.1002/ijc.24704 pmid: 19569180
[31]	Farace C, Oliver JA, Melguizo C, et al. Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells[J]. PLoS One, 2015, 10(7): e0134111. DOI: 10.1371/journal.pone.0134111. doi: 10.1371/journal.pone.0134111
[32]	Yang CT, Li JM, Chu WK, et al. Downregulation of lumican acce-lerates lung cancer cell invasion through p120 catenin[J]. Cell Death Dis, 2018, 9(4): 414. DOI: 10.1038/s41419-017-0212-3. doi: 10.1038/s41419-017-0212-3
[33]	Chen X, Li X, Hu X, et al. LUM expression and its prognostic significance in gastric cancer[J]. Front Oncol, 2020, 10: 605. DOI: 10.3389/fonc.2020.00605. doi: 10.3389/fonc.2020.00605 pmid: 32500021